Oxycodonhydrochlorid/Naloxonhydrochlorid Stada (Naloxone, Oxycodone)

Naloxone, the active ingredient in Oxycodonhydrochlorid/Naloxonhydrochlorid Stada, is a combination opioid analgesic and opioid antagonist presented as a fixed‑dose combination for oral use. It is used to manage moderate to severe pain while reducing the risk of opioid‑induced respiratory depression in adult patients.

GNH USA supplies Oxycodonhydrochlorid/Naloxonhydrochlorid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone/naloxone is a fixed‑dose combination that acts on the opioid pathway to provide analgesia while mitigating opioid‑related side effects. - Chronic moderate to severe pain: provides effective pain relief while reducing the incidence of opioid‑induced constipation. - Post‑operative pain: maintains analgesia after surgery with a lower risk of respiratory depression. - Cancer‑related pain: offers sustained pain control for patients requiring strong opioids, with built‑in opioid‑antagonist protection.

Adverse reactions may occur with the Oxycodone/naloxone combination. Monitoring and appropriate management are essential.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel motility, though less frequent than with oxycodone alone. - Dizziness: transient light‑headedness. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Hepatotoxicity: liver enzyme elevations. - Allergic reactions: rash, itching, or anaphylaxis. - Seizures: rare neurologic events. - Withdrawal syndrome: signs of opioid withdrawal if naloxone effect predominates.

When prescribing Oxycodone/naloxone, clinicians should consider patient‑specific factors and follow safety guidelines. - Assess pain severity: ensure the combination is appropriate for moderate to severe pain. - Evaluate respiratory function: monitor patients with compromised breathing. - Review hepatic function: adjust use in patients with liver impairment. - Monitor for dependence: watch for signs of opioid misuse or addiction. - Educate on constipation: advise patients on diet, hydration, and bowel regimen. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxycodone/naloxone may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): risk of profound sedation and respiratory depression. - MAO inhibitors: can precipitate severe hypertension or serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase oxycodone plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may reduce oxycodone analgesic effect. - Diuretics: can enhance hypotensive effects. - Anticholinergics: may worsen constipation despite naloxone component.